

Index

- acamprosate, 134–135
- activation likelihood estimation (ALE), 100
- acute withdrawal, 85–86
- addiction
 - behavioral definition of, 4, 12–14
 - behavioral progression of, 9–10
 - and causality, 156–157
 - chemical, 6–12
 - as chronic brain disease, 130–132
 - classification systems of, 6–9
 - clinical definition/diagnosis of, 2, 6–9
 - dark side of, 90–91
 - demography of, 5
 - mental disorders and, 4
 - phenomenology of, 4
 - rates of, 1, 149
 - stigma of, 5–6
- addiction theories
 - allostatic, 36–38
 - brain disease model, 9–12
 - cue-elicited craving, 40
 - future of, 40–41
 - impaired response inhibition and salience attribution syndrome (iRISA), 38–40
 - incentive sensitization, 34–36
- adolescence, 127, 149–150
- Adolescent Brain Cognitive Development (ABCD) study, 32
- agonists, 66
- Aharonovich, E., 140
- Ahmed, S. H., 12
- alcohol use
 - action areas of, 68
 - and anhedonia in protracted withdrawal, 87
 - appetitiveness, 103
 - behavioral effects of, 10
 - brain mechanisms of, 71–73
 - craving studies, 98–99, 102
 - demographics of, 5
 - and dopamine, 53
 - electrophysiological markers, 89
 - and endophenotypes, 153–154
 - intoxication symptoms, 64–65
 - late positive potential (LPP), 102
 - pharmacological interventions, 133–135
 - and social class, 41
 - stigma of, 5
 - withdrawal symptoms, 83
- allostatic theory, 36–38, 90–91
- allosteric potentiator, 134
- α power, 88–89
- American Psychiatric Association (APA), 6
- amotivation, 88
- amphetamine use
 - action areas of, 66
 - behavioral addiction of, 9–10
- amygdala volume
 - and alcohol use, 73
 - and cannabis use, 28
 - and the cue-elicited craving model, 40
 - and emotion regulation, 102
- Anagnostaras, S. C., 35
- anhedonia, 88
- antagonists, 66
- antireward system, 12
- anxiety
 - and cannabis use, 41
 - and high β activity, 88–89
 - internet/video game addiction, 94
- appetitiveness, 103–105
- arterial spin labeling, 100
- attention
 - and cognitive behavior therapy (CBT), 135
 - and craving, 105–106

- attention deficit/hyperactivity disorder (ADHD), 116–117
- Babor, T. F., 5
- backward masking, 106
- Balleine, B. W., 137
- Barratt Impulsiveness Scale, 115, 117
- Bauer, L. O., 89
- Begleiter, H., 69
- behavior prediction, 32
- behavior sensitizing experiments, 9
- behavioral addiction, 12–14
- behavioral drug treatment interventions, 135–137
- Berridge, K. C., 35
- β power
 - and anxiety, 89–90
 - and craving, 101
- β spectral power, 101
- Bickel, W. K., 136
- biochemical imaging, 27–28
- biomarkers, 28
- blood oxygenated level dependent (BOLD) signal, 25
- Bobzean, S. A., 156
- Boeijinga, P. H., 135
- Boileau, L., 36
- Bonson, K. R., 102
- brain
 - adolescent, 149–150
 - drug effects on mesocorticolimbic reward system, 11
- brain disease model (addiction), 2, 9–12, 130–132
- brain function
 - during protracted withdrawal, 88
 - during withdrawal, 86
 - hijacking by drugs, 104–105
 - and impulsivity, 123
 - and intoxication, 68–73
 - and love, 30
 - measurement of, 22–24
- bupropion, 134
- cannabis use
 - action areas of, 68
- behavioral effects of, 10
- craving, 100–101
- endocannabinoid system, 53
- and endophenotypes, 153
- and genetics, 29
- longitudinal study of, 156–157
- and perceived stress, mood, 40–41
- and stress, 161
- treatment outcomes, 140
- withdrawal symptoms, 83–84
- Carroll, K. M., 134, 140
- Casey, B. J., 149
- Centers for Disease Control and Prevention (CDC), 43
- cerebral blood flow (CBF), 86
- chemical addiction, 6–12
- Childress, A. R., 102–103, 104–105
- Chocyk, A., 150
- choline, 27
- Cicero, T. J., 5
- Clark, L., 121, 123
- classical conditioning experiments, 9
- cocaine
 - action areas of, 68
 - acute withdrawal, 86
 - appetitiveness, 103
 - craving studies, 100
 - and dopamine, 52
 - during protracted withdrawal, 88
 - electrophysiological markers, 88–90
 - and the iRISA theory, 38
 - late positive potential (LPP), 102
 - pharmacological interventions, 134
 - treatment outcomes, 140
 - withdrawal symptoms, 83
- cognitive behavioral models, 135–137
- cognitive behavioral therapy (CBT), 136, 138, 140
- cognitive impairment and addiction, 12
- compulsive disorders, 12–13
- Conklin, C. A., 98
- contingency management, 136
- Corbit, J. D., 36
- Costello, M. R., 137

Index

175

- craving
 - and the allostatic theory, 38
 - and attention, 105–106
 - contextual cues, 102
 - and the cue-elicited craving model, 40
 - cue-reactivity paradigms, 99–101
 - after death, 110
 - defined and research history, 98–99
 - neural mechanisms of, 101
 - neurological underpinnings of, 101–102
 - neuromolecular mechanisms, 106–107
 - and reward system hijacking, 103–105
- creatine, 27
- cue-elicited craving theory, 40
- cue-reactivity approach
 - and craving, 99
 - and methadone, 133
 - paradigms, 99–101
- Dackis, C. A., 86
- Dagher, A., 13
- Daglish, M. R., 104–105
- Decade of the Brain, 130
- delay discounting, 115, 123–125, 137
- demographics
 - and drug use, 5
 - and impulsivity, 127
- demography of addiction, 5
- dendritic alterations (brain), 106–107
- depression
 - and cannabis use, 41
 - genetic risk for, 151
- DeWitt, S., 40
- diagnosis of addiction, 6–7
- Diagnostic and Statistical Manual of Mental Disorders* (DSM), 2, 6
- diffusivity, 25
- diffusion tensor imaging (DTI), 24
- disulfiram, 135
- Domino, E. F., 69, 88
- dopamine
 - and ADHD, 116–117
 - in behavioral activation and effort, 56
 - and craving, 100
 - and hedonistic response, 10–11
 - and hormones, 156
 - and reward learning mechanisms, 51–53
 - and the incentive-sensitization model, 35
 - and the iRISA theory, 38
 - during protracted withdrawal, 87–88
- dopamine-depletion hypothesis, 86
- drug classification, 66
- Drug Enforcement Administration (DEA), 2
- drug expectations, 75
- drug treatment interventions
 - behavioral, 12, 135–137
 - combined approaches to, 137–139
 - legislation versus cost, 143–144
 - outcomes, 138–140
 - peer influence on, 142–143
 - pharmacological, 132–135
- drug treatment protocol, 131–132
- drugs (DEA schedule), 3
- Drummond, D. C., 98
- Ducci, F., 150, 151
- Dunedin Multidisciplinary Health and Development Study, 156–157
- Dunning, J. P., 102
- dysphoria, 82
- ecological validity (craving), 99–100
- ecstasy. *See* MDMA
- effort–reward calculation, 56
- electroencephalography (EEG)
 - and alcohol endophenotypes, 153–154
 - and brain mechanism, 69
 - and craving, 101–102
 - performance of, 22–24
 - and withdrawal, 88–90
- endophenotype, 118, 150–155
- environment, 102
- enzyme-linked receptors, 66
- Ersche, K. D., 117, 118, 120, 125
- etiology of addiction, 6
- Evoy, K. E., 134
- excitatory post-synaptic potential, 22
- FBJ murine osteosarcoma viral oncogene homolog B (FosB), 106–107, 110
- Fehr, C., 85

- Feldstein Ewing, S. W., 136
 fetal alcohol syndrome, 4
 Filbey, F. M., 5, 13, 40–41, 100, 101, 103–104
 final common pathway, 53–54
 five-choice serial reaction time task (5CSRTT), 121, 125
 food addiction, 12–13
 fractional anisotropy, 25
 Franken, I. H., 89, 102
 Franklin, T. R., 100
 functional MRI (fMRI)
 and adolescence, 60
 and backward masking, 105–106
 and brain mechanism, 71–73
 and cognitive behavioral therapy (CBT), 136
 craving studies, 99, 133–134
 description of, 25
 and sex in addiction, 153
- Gallinat, J., 13, 100
 gambling addiction, 12
 γ-aminobutyric acid (GABA)
 and acamprosate, 134–135
 and acute withdrawal symptoms, 86
 and alcohol use, 68, 153
 and hedonistic response, 10
 gender and addiction, 5, 155–156
 gene expression receptors, 66
 genetics
 and addiction, 5, 55–56, 150–155
 and drug expectancy, 75
 and impulsivity, 118
 and limitations to neuroimaging, 29
 ΔFosB, 106–107
 George, O., 90, 100
 Gerbing, D. W., 115
 Giorgio, A., 1, 149
 Glenn, S. W., 90
 glucose metabolism, 70–71
 go/no go test, 119
 Gogtay, N., 1, 2, 149
 Gold, M. S., 85
 Goldman, D., 150, 151
 Goldstein, R. Z., 38, 39, 139
- Gooding, D. C., 89
 Gould, K. L., 86
 G protein-coupled receptor, 66
 Gritz, E. R., 89
- half-life (substance), 82–85
 Hariri, A. R., 150, 152
 Hasan, K. M., 1, 149
 hedonistic set point, 35
 Heinze, M., 102
 Hendriks, V. M., 102
 heritability, 150
 Herning, R. I., 101
 heroin use
 electrophysiological markers, 88
 hijacking the brain, 105
 late positive potential (LPP), 102
 withdrawal symptoms, 83
 Herrmann, M. J., 102
 Holden, C., 12
 homeostasis, 36–38
 Hommer, D. W., 40
 hormones and dopamine, 156
 hypersensitization, 35
 hypothalamic–pituitary–adrenal axis (HPA), 90
- impaired response inhibition and salience attribution syndrome (iRISA), 38–40
 Impulse Behavior Scale (IBS), 117
 impulsivity
 in adolescence, 127–128
 defined, 114–116
 and delaying discounting of reward, 123–125
 and inhibitory control, 121
 nature of, 117–120
 neuropharmacology of, 116–117
 and risky decision making, 120–121
 incentive salience, 35, 47
 incentive-sensitization theory, 34–36, 103–104
 inhibitory control, 121, 140
 inhibitory post-synaptic potential, 22
International Classification of Diseases (ICD), 2, 6

Index

177

- internet/video game addiction
 - as behavioral addiction, 14
 - separation anxiety, 94
- interoceptive processes, 40
- intoxication (drug)
 - action areas of, 66–68
 - brain mechanisms of, 68–73
 - defined, 64–65
 - modulators of, 73–75
 - pharmacodynamics of, 66
- intracranial self-stimulation experiments, 9, 48
- ion channel receptors, 66
- ionic gradients, 22
- Iowa gambling task (IGT), 120–121

- Jarvis, M. J., 5
- Jessie's Law, 144
- Johnson, T. S., 134

- Kalivas, P. W., 53
- Ketcherside, A., 41
- Kim, J. E., 13
- King, D. E., 88
- Kish, S., 16
- Knott, V. J., 88, 101
- Kober, H., 136
- Konova, A. B., 137, 139
- Koob, G. F., 12, 35, 36, 37, 90–91
- Kourosh, A. S., 13
- Kuczenski, R., 9
- Kuhn, S., 13, 100

- Landes, R. D., 136
- late positive potential (LPP), 102
- Le Moal, M., 35, 36, 37, 90–91
- Lebel, C., 1, 149
- Leith, N. J., 9
- Lenoir, M., 12
- Lewis, C. C., 136
- ligands, 66
- limbic cortex activation, 102
- Littel, M., 89
- Liu, X., 101
- Loughead, J., 133
- love and brain function, 30

- LSD (lysergic acid diethylamide), 15, 66
- magnetic resonance imaging (MRI), 12, 24–27
- magnetic resonance spectroscopy (MRS), 27
- magnetoencephalography (MEG), 22–23
- Marijuana Problem Scale (MPS), 101
- Martinotti, G., 87
- masked cue task, 105–106
- McDonough, B. E., 102
- MDMA (3,4-methylenedioxymethamphetamine), 15, 66
- mechanisms of addiction, 9–12
- memory and addiction, 56–58
- mental disorders and addiction, 4
- mesolimbic reward system (brain)
 - and behavioral addiction, 13–14
 - changes during addiction, 10–12
 - and the cue-elicited craving model, 40
 - as reward system, 49
- metabolites (brain tissue), 27
- methadone, 133
- methamphetamine use, 53
- monetary incentive delay task, 60
- morphine, 9
- motivation
 - and future drug use prediction, 60
 - and reward learning mechanisms, 47–58
- motivational enhancement therapy (MET), 136
- motivational interviewing (MI), 136, 138
- Myrick, H., 100, 101

- N*-acetylaspartate (NAA), 27
- Namkoong, K., 102
- National Institutes of Health (NIH), 31
- natural reinforcers, 12
- neonatal abstinence syndrome, 4, 93
- Nestler, E. J., 106
- neuroimaging studies
 - and addiction activity, 12
 - and behavior prediction, 32
 - craving, 99–101
 - diffusion tensor imaging (DTI), 24

- neuroimaging studies (cont.)
 - electroencephalography (EEG), 22–24, 69, 88–90, 101–102, 153–154
 - functional MRI (fMRI), 25, 60, 71–73, 99, 105–106, 133–134, 136, 153
 - and impulsivity, 119
 - limitations of, 28–29
 - magnetic resonance imaging (MRI), 24–27
 - magnetic resonance spectroscopy (MRS), 27
 - magnetoencephalography (MEG), 22–23
 - of behavioral addiction, 13–14
 - of combined drug interventions, 137–138
 - positron emission tomography (PET), 12, 26–28, 52–53, 69–71, 100
 - single-photon emission computed tomography (SPECT), 26, 27–28
 - structural MRI, 24
- Niaura, R. S., 98
- nicotine use
 - action areas of, 66–68
 - and brain mechanism, 68–70
 - and craving, 100, 101–102
 - and the cholinergic system, 53
 - delay discounting, 124
 - demographics of, 5
 - pharmacological interventions, 133–134
 - and social class, 41
 - withdrawal symptoms, 83, 87
- nucleus accumbens
 - and acute withdrawal symptoms, 86
 - and ADHD, 116–117
 - as common addiction pathway, 54
 - and craving, 106–107, 109
 - and dopamine, 49–52
- Nutt, D. J., 104
- O'Brien, C. P., 13
- Ogawa, S., 25
- opioid use
 - action areas of, 68
 - addiction from birth, 93
 - behavioral effects of, 10
 - demographics of, 5
 - and hedonistic response, 11
 - and the opioid system, 53
 - pharmacological interventions, 133
 - as public health concern, 43–45, 162
 - treatment cost, 143–144
- opponent-process theory, 36, 90–91
- Orsini, C., 82
- P300, 101–102
- Pagliaccio, D., 28
- Papageorgiou, C. C., 89
- Pavlovian conditioning, 98–99
- peer recovery specialists, 142–143
- pharmacodynamics, 66
- pharmacological interventions, 132–135
- phencyclidine (PCP), 68
- phenomenology of addiction, 4
- place preference, 9–10
- pleasure molecule. *See* dopamine
- Porjesz, B., 69, 89, 153, 154
- positron emission tomography (PET)
 - and brain mechanism, 69–71
 - craving studies, 100
 - dopamine studies, 27–28, 53
 - post-acute withdrawal syndrome, 87–88
- post-traumatic stress disorder (PTSD), 15–16, 161
- Potenza, M. N., 137–138
- prefrontal cortex
 - and craving, 100, 106–107
 - and decision making, 120–121
 - and dopamine, 51–53
 - during withdrawal, 86
 - dysfunction and relapse, 85–86
 - and the iRISA theory, 38–39
 - and reinstatement, 54
- pre-potent response, 115
- probability discounting, 124
- Probst, C. C., 12
- protracted withdrawal symptoms, 87–88
- psychedelic drug therapeutic benefits, 15–16
- psychiatric disorders and addiction, 5
- pyramidal cells, 22
- radionucleotides, 27
- radiotracer, 100

Index

179

- Rangaswamy, M., 153, 154
 receptors, 66
 Reid, M. S., 101
 reinstatement experiments
 and drug relapse, 9
 and final common pathway, 53–54
 relapse prediction
 for drug-addicted patients, 131
 electrophysical makers for, 89–90
 prefrontal cortex and, 85–86
 reinstatement experiments, 10
 relapse prevention, 140
 resting-state functional connectivity (rsFC),
 71
 reward deficiency syndrome, 55
 reward system
 and addiction, 10–12
 and behavioral-drug treatment
 interventions, 137
 and craving, 103–105
 and incentive salience, 35
 and motivation, 47–58
 risk factors, 5, 149–150
 risky decision making, 120–121
 Robinson, T. E., 35, 50, 99
 Roemer, R. A., 88

 Salamone, J. D., 56, 57
 Schacht, J. P., 28, 153, 155
 Schedule I drugs, 2–3
 Schneider, F., 99
 school dropout rate and addiction, 4
 Sell, L. A., 104
 Seltenhammer, M., 109
 serotonin, 68
 sex addiction
 appetiteness, 103–104
 as behavioral addiction, 12–13
 Shaw, P., 1, 150
 shopping addiction, 13
 Shufman, E., 88
 single-photon emission computed
 spectroscopy (SPECT), 27–28,
 69
 Sinha, R., 86
 Skinner, M. D., 135

 social class
 and addiction, 5
 and drug use, 41
 Sofuoglu, M., 134, 137
 Solomon, R. L., 36
 stimulant use
 behavioral effects of, 10
 demographics of, 5
 stop signal reaction time (SSRT), 119, 121,
 123
 stress (adolescent), 150, 161
 structural MRI, 24
 substance use disorder (SUD)
 addiction as, 2
 behavioral symptoms of, 12–13
 classification systems of, 6–7
 sugar addiction, 12–13
 superconducting quantum interference
 device (SQUID), 22
 Surwillo, W. W., 88
 sympathomimetic action, 86

 Tanabe, J., 86, 87
 tanning addiction, 12, 13
 Teklezgi, B. G., 133
 tetrahydrocannabinol (THC), 68
 thalamus, 86
 Tiffany, S. T., 98–99, 105
 tolerance
 and the allostatic theory, 36–38
 brain adaptation and, 11
 and substance use, 4
 sugar, 12–13
 tractography, 25
 transduction, 66

 unemployment rate and addiction, 4

 Vaituzis, A. C., 1, 150
 van de Laar, M. C., 102
 van Eimeren, T., 12
 Venables, P. H., 88
 Verdejo-Garcia, A., 140
 Vogeler, T., 134
 Volkow, N. D., 13, 38, 39, 40, 52, 53–54, 71,
 75, 85, 86, 88

- wait circuit, 124
- waiting, 125
- Wang, G. J., 71
- Warren, C. A., 102
- Weeks, J. R., 9
- Wexler, B. E., 136
- Wierenga, L. M., 150
- Winterer, G., 89
- withdrawal
 - acute, 85–86
 - and the allostatic theory, 36
 - between systems adaptations, 90–91
 - brain adaptation and, 11
 - brain function during, 86
 - and dark side of addiction, 11
 - defined, 81–82
 - electrophysiological mechanisms of, 88–90
 - and incentive sensitization model, 35
 - and the iRISA theory, 39
 - protracted, 87–88
 - and substance use, 4
 - sugar, 12
 - symptoms and classification of, 82–84
- Wong, D. F., 100
- Worhunsky, P. D., 13
- World Health Organization, 2, 6
- Wrase, J., 99
- Wray, J. M., 105
- young adult. *See* adolescence
- Young, K. A., 105
- Zubieta, J. K., 86